| Mr Dwayne Dennis Callwood, MD | |
|
1234 Huffman Mill Road, Burlington, NC 27215 | |
| (336) 538-2374 | |
| (336) 584-6811 |
| Full Name | Mr Dwayne Dennis Callwood |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 35 Years |
| Location | 1234 Huffman Mill Road, Burlington, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023194479 | NPI | - | NPPES |
| 20860 | Other | NC | BCBS |
| 7116 | Other | NC | PARTNERS |
| 69723 | Other | NC | MEDCOST |
| 7920860 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 35857 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Alamance Regional Medical Center | Burlington, NC | Hospital |
| Halifax Regional Medical Center Inc | Roanoke rapids, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vidant Medical Group Llc | 0345343893 | 849 |
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Entity Name | Halifax Regional Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992846570 PECOS PAC ID: 5496664062 Enrollment ID: O20031125000253 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Entity Name | Southeastern Regional Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427282045 PECOS PAC ID: 7012058548 Enrollment ID: O20100106000556 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Dwayne Dennis Callwood, MD 1234 Huffman Mill Road, Burlington, NC 27215-8700 Ph: (336) 538-1234 | Mr Dwayne Dennis Callwood, MD 1234 Huffman Mill Road, Burlington, NC 27215 Ph: (336) 538-2374 |
News Archive
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Before "Medicare for All," there was just Medicare, the very popular program that serves 60 million Americans age 65 and older or younger people with certain disabilities.
Though the question of whether Democratic leaders would include a public option in the Senate's health reform bill has held the spotlight, a variety of other big issues also remain unresolved, The Hill reports.
The first trial of a new model for testing Alzheimer's treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.
› Verified 4 days ago
Dr. Ayesha Ali, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 729 Meadowood Dr, Burlington, NC 27215 Phone: 347-606-0485 | |
Dr. Fozia Muhstaqe Khan, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2991 Crouse Ln, Burlington, NC 27215 Phone: 336-586-0994 Fax: 336-586-9363 | |
Dr. Muhammad Arida, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1236 Huffman Mill Rd Ste 130, Burlington, NC 27215 Phone: 336-438-1060 | |
Janak Kantilal Choksi, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1236 Huffman Mill Rd, Suite #120, Burlington, NC 27215 Phone: 336-538-7725 Fax: 336-538-7785 | |
Dr. Anna Melissa Solum, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1234 Huffman Mill Rd, Burlington, NC 27215 Phone: 336-538-1234 Fax: 336-538-2390 | |
Dr. Munsoor Lateef, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2903 Professional Park Dr, Suite D, Burlington, NC 27215 Phone: 336-584-4913 Fax: 336-584-4914 |